SOPHiA GENETICS Community

NasdaqGS:SOPH Community

1 Narratives written by author
0 Comments on narratives written by author
3 Fair Values set on narratives written by author

SOPHiA GENETICS

AN

AnalystConsensusTarget

Consensus Narrative from 5 Analysts

Expedited Implementation And New US Signings Will Boost Future Impact

Key Takeaways Expansion in the U.S. market and major new customer acquisitions like Mount Sinai are poised to significantly boost revenue and market share. Strategic product launches and platform optimizations are anticipated to improve margins and drive revenue growth across clinical and BioPharma sectors.

US$6.80

FV

55.0% undervalued

20.28%

Revenue growth p.a.

0

0

3

Updated